Navigation Links
Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
Date:3/17/2009

PRINCETON, N.J., March 17 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that the following clinical and preclinical abstracts are expected to be the subject of poster presentations at the Annual Meeting of the American Association for Cancer Research (AACR), being held April 18-22, 2009 in Colorado:

  • "A Phase I, open-label, dose-escalation, multi-dose study of MDX-1401 (defucosylated human antiCD30 monoclonal antibody) in patients with CD30-positive refractory/relapsed Hodgkin's lymphoma" (Abstract #1227), R. Thertulien - Poster presentation from 1:00 to 5:00 p.m. local time on Sunday, April 19, 2009.

  • "Efficacy of MDX-1110, an anti-Fucosyl-GM1 antibody in a SCLC tumor model" (Abstract #838), B. Chen - Poster presentation from 8:00 to 12:00 p.m. local time on Sunday, April 19, 2009.

  • "The critical role of cleavable linkers for minor groove binding alkylating agent (MGBA) based antibody-drug conjugates" (Abstract #1722), S. Gangwar - Poster presentation from 1:00 to 5:00 p.m. local time on Sunday, April 19, 2009.

  • "Development of anti-Glypican 3 therapeutic antibodies" (Abstract #1233), L. Lu - Poster presentation from 1:00 to 5:00 p.m. local time on Sunday, April 19, 2009.

  • "Efficacy and Toxicity of anti-mesothelin antibody drug conjugate" (Abstract #3235), C. Rao - Poster presentation from 8:00 to 12:00 p.m. local time on Tuesday, April 21, 2009.

Abstracts and information about the AACR and its Annual Meeting may be found at www.aacr.org.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Over forty of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with the most advanced product candidates currently in Phase 3 clinical trials, the subject of regulatory applications for marketing authorization or approved in Canada and Europe. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Medarex Announces Allowance of Investigational New Drug Application for Companys First Antibody-Drug Conjugate, MDX-1203
2. Medarex to Present at the 27th Annual J.P. Morgan Healthcare Conference
3. Medarex to Present at the RBC Capital Markets Healthcare Conference
4. Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
5. Medarex Announces 2008 Third Quarter Financial Results
6. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
7. Medarex to Present at the UBS Global Life Sciences Conference
8. Medarex to Present at the Thomas Weisel Partners Healthcare Conference
9. BioWa and Medarex Announce License of BioWas COMPLEGENT(TM) Technology
10. Medarex Announces July 10 Live Webcast of R&D Day Event
11. Medarex to Present at the Jefferies Second Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... OXFORD, England , Aug. 16, 2017  Kingfisher ... executive search and leadership development, and Virdis Group, global executive ... an exclusive alliance that enables clients to leverage the expertise ... "For our clients here in the Boston ... a diverse population of leadership talent throughout the US, ...
(Date:8/15/2017)... ... August 15, 2017 , ... Nanomedical Diagnostics ... biotherapeutics development, announces the launch of the new NHS Agile biosensor chip ... binding data for a wide range of molecules, including small and large molecules, ...
(Date:8/15/2017)... Kenosha, Wisconsin (PRWEB) , ... August 15, 2017 ... ... introduced a new family of 6” modular downlights designed to stay tightly sealed ... applications, including areas where damp and wet location listings just aren't enough, such ...
(Date:8/15/2017)... Allentown, PA (PRWEB) , ... August 15, 2017 ... ... and encrypted shopping cart. Now mobile responsive, the new website makes it ... lab or anywhere in between. Users can now find detailed product information, educational ...
Breaking Biology Technology:
(Date:5/16/2017)... TEANECK, N.J. , May 16, 2017  Veratad ... leading provider of online age and identity verification solutions, ... the K(NO)W Identity Conference 2017, May 15 thru May ... Ronald Regan Building and International Trade Center. ... across the globe and in today,s quickly evolving digital ...
(Date:4/18/2017)... , April 18, 2017  Socionext Inc., a global expert in ... media edge server, the M820, which features the company,s hybrid codec ... provided by Tera Probe, Inc., will be showcased during the upcoming ... NAB show at the Las Vegas Convention ... Click ...
(Date:4/11/2017)... Apr. 11, 2017 Research and Markets has ... report to their offering. ... The global eye tracking market to grow at a CAGR of ... Eye Tracking Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
Breaking Biology News(10 mins):